Clinical Neuropsychopharmacology and Addiction
September 1, 2026
Beatrice Dal Bianco, Matteo Buonarroti, Alessandro Lo Jacono et al.
Background: Epidemiological data on psychedelic use in Italy is limited. In this study, Italian responders in the Global Psychedelic Survey 2025 were subanalyzed to describe patterns of use, motivations, subjective experiences, and health correlates. Methods: Adults (≥21 years) with lifetime psychedelic exposure, residing in or born in Italy or San Marino, were surveyed in a web-based,...
The British Journal of Psychiatry
June 18, 2025
Kyle T. Greenway, Nicolas Garel, Lê-Anh Dinh-Williams et al.
8 citations
Background Ketamine exerts potent but transient antidepressant effects in treatment-resistant depression (TRD). Combinations of ketamine and psychotherapy have attracted interest, but no trial has investigated a psychedelic model of ketamine–psychotherapy for TRD to our knowledge. Aims This secondary analysis of a randomised clinical trial (RCT) explores the therapeutic effects and experiential...
Nature Medicine
June 3, 2025
Chloé Pronovost-Morgan, Kyle T. Greenway, Leor Roseman et al.
26 citations
Psychedelic substances exhibit complex interactions with the 'set and setting' of use, that is, the mental state of the user and the environment in which a psychedelic experience takes place. Despite these contextual variables' known importance, psychedelic research has lacked methodological rigor in reporting extra-pharmacological factors. This study aimed to generate consensus-based...
Expert Review of Clinical Pharmacology
March 1, 2025
Danny Diep, Sara de la Salle, Julien Thibault Lévesque et al.
8 citations
Since its synthesis in 1962, ketamine has been widely used in diverse medical contexts, from anesthesia to treatment-resistant depression. However, interpretations of ketamine's subjective effects remain polarized. Biomedical frameworks typically construe the drug's experiential effects as dissociative or psychotomimetic, while psychedelic paradigms emphasize the potential therapeutic merits of...
Journal of psychopharmacology (Oxford, England)
February 26, 2025
Sara de la Salle, Jennifer L Phillips, Pierre Blier et al.
3 citations
A sub-anesthetic dose of ketamine, an N-methyl-D-aspartate receptor (NMDAR) antagonist, produces robust antidepressant effects in treatment-resistant major depressive disorder (MDD). The mismatch negativity (MMN) is reliant on glutamatergic neurotransmission and reduced by NMDAR antagonists. The MMN may characterise the neural mechanisms underlying ketamine's effects. This study examined the...
Psychedelic Med (New Rochelle)
December 2, 2024
Sara G. Gloeckler, Alexandre Lehmann, Sara de la Salle et al.
4 citations
Background: The resurgent interest in psychedelic-assisted therapy for conditions like depression, end-of-life anxiety, and post-traumatic stress disorder is generating highly promising results. Within this therapeutic context, music's role is multifaceted, seen as a critical environmental component and even akin to a hidden therapist. Contemporary clinical protocols often advocate for music...
Scientific Reports
July 17, 2024
Sara de la Salle, Hannes Kettner, Julien Thibault Lévesque et al.
21 citations
Recent clinical trials have found that the serotonergic psychedelic psilocybin effectively alleviates anxiodepressive symptoms in patients with life-threatening illnesses when given in a supportive environment. These outcomes prompted Canada to establish legal pathways for therapeutic access to psilocybin, coupled with psychological support. Despite over one-hundred Canadians receiving...
Journal of Studies on Alcohol and Drugs
July 1, 2022
Timothy I. Michaels, Lebert Lester, Sara de la Salle et al.
19 citations
OBJECTIVE: Despite strong evidence for the safety and efficacy of ketamine in the treatment of mood disorders, the enrollment of Black, Indigenous, and People of Color (BIPOC) has not been a focus of this research. Health disparities in the treatment of mood disorders in BIPOC indicate a strong need to understand the clinical, social, and pharmacological aspects of this novel treatment in...
Journal of Psychedelic Studies
July 15, 2021
Zoe W. Jahn, Joel A Lopez, Sara de la Salle et al.
36 citations
Abstract Background Few studies have assessed the epidemiology of hallucinogenic substance use among racial and ethnic groups of varying age cohorts. Use of psychedelic substances may differ among people of color (POC), due to factors such as stigma and discriminatory drug enforcement practices against POC. The lack of inclusion of POC in psychedelic research further underscores the importance...
Journal of Medical Ethics
July 12, 2021
Dana Strauss, Sara de la Salle, Jordan Sloshower et al.
70 citations
There is a growing resurgence in the study of psychedelic medicines for the treatment of mental health and substance use disorders. However, certain early investigations are marred by questionable research methods, abuses against research participants, and covert Central Intelligence Agency financial involvement. The purpose of this study was to understand how and to what extent people of...
Experimental and Clinical Psychopharmacology
June 7, 2021
Colleen Fogg, Timothy I. Michaels, Sara de la Salle et al.
53 citations
Emerging evidence from randomized, double-blind, placebo-controlled clinical trials suggests psychedelic compounds such as 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and lysergic acid diethylamide (LSD), when administered as an adjunct to psychotherapy, that is, psychedelic-assisted psychotherapy (PAP), may be beneficial for treating substance use disorders, posttraumatic stress...